Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Seattle Genetics, Astellas deal

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-15ME. Agensys, which received an

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE